3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
177
Lung Neoplasms
59
Neoplasms
24
Neoplasm Metastasis
17
Parkinson Disease 4, Autosomal Dominant Lewy Body
13
Mesothelioma, Malignant
12
Carcinoma
11
Colorectal Neoplasms
10
Mesothelioma
9
Meningeal Carcinomatosis
8
Melanoma
7
Brain Neoplasms
7
Pancreatic Neoplasms
6
Adenocarcinoma of Lung
6
Advanced Solid Tumors
5
Uterine Cervical Neoplasms
4
Ovarian Neoplasms
4
Neoplasms by Site
4
Colonic Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Rectal Neoplasms
3
Non-squamous Non-small Cell Lung Cancer
3
Neoplasms by Histologic Type
3
NSCLC
3
Lung Diseases
3
Head and Neck Neoplasms
3
Carcinoma, Transitional Cell
3
Carcinoma, Bronchogenic
3
Adenocarcinoma
3
Thoracic Neoplasms
2
Interventions
durvalumab
2
tremelimumab
1
ceralasertib
1
aflutinib
1
Radiotherapy
1
Pemetrexed
1
Gemcitabine
1
Cisplatin
1
Carboplatin
1
Albumin-Bound Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Non Small Cell Lung Cancer NSCLC
×
Pemetrexed
×
1 year
×
Clear all
NCT03164616
2026-03-13
POSEIDON
AstraZeneca
Phase 3
Active not recruiting
1,186 enrolled
26 charts
1 FDA